利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.01 秒)

    Paired polypeptides
    13.
    发明公开
    Paired polypeptides 失效
    配对多肽

    公开(公告)号：EP0447133A2

    公开(公告)日：1991-09-18

    申请号：EP91301927.9

    申请日：1991-03-07

    申请人： ORION-YHTYMA OY

    发明人： Krupey, John

    IPC分类号： G01N33/58 ,  G01N33/532 ,  C07K4/00 ,  G01N33/533

    CPC分类号： G01N33/582 ,  G01N33/533 ,  G01N33/583 ,  Y10S435/968 ,  Y10S436/80

    摘要： The invention provides a binding assay reagent comprising a backbone polypeptide comprising glutamic acid residues and lysine residues is proportions such that the backbone polypeptide has a net positive charge, said backbone polypeptide having a molecular mass of ≧ 2.0 x 10⁵ Daltons; an optical dye label covalently bound to the backbone polypeptide, a specific binding molecule covalently bound to the backbone polypeptide, and an enhancing peptide associated with the backbone polypeptide, said enhancing peptide being comprised of a mixture of a) acidic and basic amino acid monomer residues having opposite stereochemical configurations or b) mixtures of homopolymers of acidic amino acids and basic amino acids wherein the homopolymers may be of the same or different stereochemical configurations, and wherein said enhancing peptide is electrically neutral or has a net negative charge. The binding assay reagents exhibit enhanced binding activity over that of the dye labelled polypeptides alone and also enhance the sensitivity of the binding assay by providing increased amounts of optical label.

    摘要翻译： 本发明提供了包含含有谷氨酸残基的主链多肽和赖氨酸残基的结合测定试剂，其比例使得主链多肽具有净正电荷，所述主链多肽具有≥2.0×10 5道尔顿的分子量; 与骨架多肽共价结合的光学染料标记，与骨架多肽共价结合的特异性结合分子和与骨架多肽相关的增强肽，所述增强肽由a）酸性和碱性氨基酸单体残基 具有相反的立体化学构型或b）酸性氨基酸和碱性氨基酸的均聚物的混合物，其中均聚物可以具有相同或不同的立体化学构型，并且其中所述增强肽是电中性的或具有净负电荷。 结合测定试剂与单独的染料标记的多肽相比表现出增强的结合活性，并且还通过提供增加量的光学标记来增强结合测定的灵敏度。

    ANTIOXIDANT COMPOUNDS
    14.
    发明公开
    ANTIOXIDANT COMPOUNDS 失效
    抗氧化剂

    公开(公告)号：EP0910354A1

    公开(公告)日：1999-04-28

    申请号：EP97920759.0

    申请日：1997-05-02

    申请人： ORION-YHTYMA OY

    发明人： AHOTUPA, Markku ,  KANGAS, Lauri

    IPC分类号： A61K31 ,  A61P9 ,  A61P17 ,  A61P31

    CPC分类号： A61K31/138

    摘要： A new use of halogenated triphenylethylene derivatives for lowering levels of serum lipid peroxides and for the prevention or treatment of oxidative tissue damage induced by lipid peroxidation is disclosed. The new use includes the prevention or treatment of atherosclerosis, ischemic injury, psoriasis, inflammatory diseases, such as inflammatory bowel disease, or cardiovascular disorders, such as coronary heart disease, cardiac ischemic injury and post-ischemic cardiac arrhythmias, or the treatment of AIDS.

    IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY
    16.
    发明公开
    IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY 失效
    具有ALPHA2受体活性的咪唑衍生物

    公开(公告)号：EP0888309A1

    公开(公告)日：1999-01-07

    申请号：EP96932609.0

    申请日：1996-10-02

    申请人： ORION CORPORATION (ORION-YHTYMA OY)

    发明人： KARJALAINEN, Arja ,  HUHTALA, Paavo ,  SAVOLA, Juha-Matti ,  WURSTER, Siegfried ,  ELORANTA, Maire ,  HILLILÄ, Maarit ,  SAXLUND, Raimo ,  COCKCROFT, Victor ,  KARJALAINEN, Arja

    IPC分类号： C07D233 ,  A61K31 ,  A61P9 ,  A61P25 ,  A61P27 ,  A61P31

    CPC分类号： C07D233/56 ,  C07D233/64

    摘要： Imidazole derivatives of formula (I), wherein n is 0 or 1, R1 is hydrogen or C1-C4-alkyl, R2 is hydrogen or R2 and R3 together form a double bond, R3 is hydrogen or C1-C4-alkyl or R2 and R3 together form a double bond, R4 is hydrogen, C1-C4-alkyl, hydroxy or C1-C4-alkoxy, R5 is hydrogen or C1-C4-alkyl or R4 and R5 together with the carbon atom to which they are attached form a carbonyl group, R6, R7 and R8 are each the same or different and are independently hydrogen, C1-C4-alkyl or C2-C4-alkenyl, C3-C7-cycloalkyl, hydroxy, C1-C4-alkoxy, C1-C4-hydroxyalkyl, thiol, C1-4-alkylthio, C1-4-alkylthiol, halogen, trifluoromethyl, nitro or optionally substituted amino, X is -CHR9-(CHR10)m-, m is 0 or 1, and R9 and R10 are each the same or different and are independently hydrogen or C1-C4-alkyl; or a pharmaceutically acceptable ester or salt thereof, their preparation, use and pharmaceutical compositions comprising them are described. The compounds have affinity for alpha2 receptors and are useful e.g. in the treatment of hypertension, glaucoma, chronic or acute pain, migraine, diarrhea, common cold, ischemia, addiction to chemical substances, anxiety, especially preoperative anxiety and different neurological, musculoskeletal, psychiatric and cognition disorders or as adjuncts to anesthesia.